Call for Abstracts and Travel Awards: All authors notified by email  ︎  18 invited speakers confirmed  ︎  Save your seat! Register here until October 7  ︎  Check the programme at a glance  ︎  Interested in joining the team of volunteers? Apply now!   ︎  Become a partner of #CRSy22  ︎ 
︎    ︎    ︎    

Jeffrey W. Pollard, PhD



Professor @College of Medicine and Veterinary Medicine, University of Edinburgh




Professor Pollard graduated with first-class special honors in Zoology from Sheffield University followed by a PhD at Imperial Cancer Research Fund (now CRUK) in London. He spent a postdoctoral period at Ontario Cancer Institute in Toronto and thereafter, took a Faculty position at King’s College University of London. In 1988 he joined the Albert Einstein College of Medicine in New York where he worked for 24 years prior to coming to Edinburgh in 2013 as Director of the Medical Research Council Centre for Reproductive Health. At the Albert Einstein College of Medicine, Professor Pollard was the Louis Goldstein Swann Chair in Women’s Health, Deputy Director of the NCI funded Cancer Center, and Director of the NIH funded Center for the Study of Reproductive Biology and Women’s Health. He stepped down as MRC-Director in 2022.

Professor Pollard is a Fellow of the Royal Society of Edinburgh, Fellow of the Royal Society of Biology, Fellow of the Academy of Medical Sciences and a Fellow of the American Association for the Advancement of Sciences. He has published over 285 papers and edited several books/journal issues including “Metastasis: Mechanisms to Therapy” book published by Cold Spring Harbor Press in 2019. He has an H-impact of 110, has been in the Clarivate top 1% of cited researchers for many years, and in the 2019 assessment of research impact he is in the all-time top 0.01% of cited scientists out of ~7 million.

Prof Pollard pioneered studies on the role of macrophages in development and tumor progression. His lab was the first to demonstrate that tumour associated macrophages (TAMs) promote tumor progression and malignancy. His work has focused upon mechanisms behind these pro-tumoral actions of TAMs with a particular emphasis on metastatic disease. Current studies are emphasizing translation of mouse studies to humans, particularly in breast, ovarian, endometrial and brain cancer.  Definition of regulatory signaling pathways in macrophages has led to clinical trials that target these cells.  For these studies he was awarded the American Cancer Society Medal of Honor in basic sciences for his work in tumour immunology in 2010. In 2020 Prof Pollard founded an immunooncology company “Macomics” dedicated to translating basic science to clinical efficacy in cancer.

His current research explores the role of macrophages in homeostasis, tissue repair and cancer.

Visit the speaker’s lab here ︎︎︎
Learn more about the speaker here︎


This symposium is supported by QuantOCancer Project funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 810653.